SMStéphane Minvielle

Stéphane Minvielle

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stéphane Minvielle has a total of 810 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

    by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Intergroupe Francophone du Myélome (Ifm), Cyrille Hulin, et al.

  • Open Access

    Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

    by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Intergroupe Francophone du Myélome (Ifm), Cyrille Hulin, et al.

  • Open Access

    Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

    by Aurore Perrot, Cyrille Touzeau, Stéphane Minvielle, Cyrille Hulin, Denis Caillot, Salomon Manier, Xavier Leleu, Cécile Sonntag, Karim Belhadj, Bertrand Arnulf, et al.

  • Open Access

    Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma

    by Florence Magrangeas, Catherine Guérin-Charbonnel, Victor Bessonneau-Gaborit, Marie Denoulet, Nils Giordano, Aurore Perrot, Cyrille Touzeau, Mark van Duin, Magali Devic, Elise Douillard, et al.

    Long-term follow-up of the CASSIOPEIA trial (NCT02541383) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance therapy, in transplant-eligible patients newly diagnosed with multiple myeloma (MM). However, outcomes among CASSIOPEIA patients remain heterogeneous across treatment groups. Measurable residual disease (MRD) is a strong indicator of the depth and duration of therapeutic response and is independently associated with both PFS and overall survival (OS), but it does not fully capture the biological diversity of MM. We performed a risk prediction analysis based on transcriptomic subgroups in CASSIOPEIA patients. A subset of 628 patients was characterized using RNA sequencing and consensus clustering identified five subtypes of MM grouped into three transcriptomic risk categories, with estimated 72-month PFS rates of 70%, 51%, and 27% for low, intermediate, and high-risk groups, respectively, among patients who received daratumumab in at least one treatment phase. We showed that post-consolidation MRD negativity was higher in low- and high-risk groups compared to intermediate, and that its prognostic impact was distinct and reduced in high-risk patients. These findings indicate that transcriptomic profiling refines the prognostic value of MRD by identifying high-risk patients in whom MRD alone is insufficient to predict clinical outcome. This suggests that MRD negativity may not capture clinically relevant residual disease in this subgroup, potentially reflecting aggressive disease dynamics. Overall, these results support integrating baseline molecular features with MRD assessment and highlight the need for novel therapeutic strategies in high-risk MM.


  • Open Access

    Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma

    by Florence Magrangeas, Catherine Guérin-Charbonnel, Victor Bessonneau-Gaborit, Marie Denoulet, Nils Giordano, Aurore Perrot, Cyrille Touzeau, Mark van Duin, Magali Devic, Elise Douillard, et al.

    Long-term follow-up of the CASSIOPEIA trial ( NCT02541383 ) demonstrated superior progression-free survival (PFS) with daratumumab, both in combination with bortezomib, thalidomide, and dexamethasone during induction and consolidation, and during maintenance therapy, in transplant- eligible patients newly diagnosed with multiple myeloma (MM). However, outcomes among CASSIOPEIA patients remain heterogeneous across treatment groups. Measurable residual disease (MRD) is a strong indicator of the depth and duration of therapeutic response and is independently associated with both PFS and overall survival (OS), but it does not fully capture the biological diversity of MM. We performed a risk prediction analysis based on transcriptomic subgroups in CASSIOPEIA patients. A subset of 628 patients was characterized using RNA sequencing and consensus clustering identified five transcriptomic subtypes of MM. Long-term follow-up allowed the definition of three transcriptomic risk categories, with estimated 72-month PFS rates of 70%, 51%, and 27% for low, intermediate, and high-risk groups, respectively, among patients who received daratumumab in at least one treatment phase. In these patients, MRD negativity rates after consolidation and six months later were significantly higher in the low and high-risk groups compared with the intermediate-risk group. In the high-risk group, MRD status was not associated with PFS or OS. This suggests that, although daratumumab administered during both the induction/consolidation and maintenance phases improves the clinical outcomes of patients with activation of NSD2 or overexpressing members of the MAF family, highly aggressive minor clones may rapidly expand. These findings emphasize the need for novel therapeutic strategies in this high-risk population.

  • A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics

    by Romane Durand, Géraldine Descamps, Céline Bellanger, Christelle Dousset, Sophie Maïga, Jean-Baptiste Alberge, Jennifer Derrien, Jonathan Cruard, Stéphane Minvielle, Nicoletta Libera Lilli, et al.

    To establish a strict p53-dependent gene-expression profile, TP53−/− clones were derived from TP53+/+ and TP53−/mut t(4;14) human myeloma cell lines (HMCLs) using CRISPR/Cas9 technology. From the 17 dysregulated genes shared between the TP53−/− clones from TP53+/+ HMCLs, we established a functional p53 score, involving 13 genes specifically downregulated upon p53 silencing. This functional score segregated clones and myeloma cell lines as well as other cancer cell lines according to their TP53 status. The score efficiently identified samples from patients with myeloma with biallelic TP53 inactivation and was predictive of overall survival in Multiple Myeloma Research Foundation–coMMpass and CASSIOPEA cohorts. At the functional level, we showed that among the 13 genes, p53-regulated BAX expression correlated with and directly affected the MCL1 BH3 mimetic S63845 sensitivity of myeloma cells by decreasing MCL1-BAX complexes. However, resistance to S63845 was overcome by combining MCL1 and BCL2 BH3 mimetics, which displayed synergistic efficacy. The combination of BH3 mimetics was effective in 97% of patient samples with or without del17p. Nevertheless, single-cell RNA sequencing analysis showed that myeloma cells surviving the combination had lower p53 score, showing that myeloma cells with higher p53 score were more sensitive to BH3 mimetics. Taken together, we established a functional p53 score that identifies myeloma cells with biallelic TP53 invalidation, demonstrated that p53-regulated BAX is critical for optimal cell response to BH3 mimetics, and showed that MCL1 and BCL2 BH3 mimetics in combination may be of greater effectiveness for patients with biallelic TP53 invalidation, for whom there is still an unmet medical need.


  • Open Access

    Exploring the impact of dexamethasone on gene regulation in myeloma cells

    by Victor Bessonneau-Gaborit, Jonathan Cruard, Catherine Guerin-Charbonnel, Jennifer Derrien, Jean-Baptiste Alberge, Elise Douillard, Magali Devic, Sophie Deshayes, Loïc Campion, Frank Westermann, et al.

    Among glucocorticoids (GCs), dexamethasone (Dex) is widely used in treatment of multiple myelomas. However, despite a definite benefit, all patients relapse. Moreover, the molecular basis of glucocorticoid efficacy remains elusive. To determine genomic response to Dex in myeloma cells, we generated bulk and single-cell multi-omics data and high-resolution contact maps of active enhancers and target genes. We show that a minority of glucocorticoid receptor-binding sites are associated with enhancer activity gains, increased interaction loops, and transcriptional activity. We identified and characterized a predominant enhancer enriched in cohesin (RAD21) and more accessible upon Dex exposure. Analysis of four gene-specific networks revealed the importance of the CTCF–cohesin couple and the synchronization of regulatory sequence openings for efficient transcription in response to Dex. Notably, these epigenomic changes are associated with cell-to-cell transcriptional heterogeneity, in particular, lineage-specific genes. As consequences,BCL2L11-encoding BIM critical for Dex-induced apoptosis andCXCR4protective from chemotherapy-induced apoptosis are rather up-regulated in different cells. In summary, our work provides new insights into the molecular mechanisms involved in Dex escape.


  • Open Access

    High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma

    by Mehmet Kemal Samur, Marco Roncador, Anil Aktas Samur, Mariateresa Fulciniti, Abdul Hamid Bazarbachi, Raphael E. Szalat, Masood A. Shammas, Adam S. Sperling, Paul G. Richardson, Florence Magrangeas, et al.

    High-dose melphalan (HDM) improves progression-free survival in multiple myeloma (MM), yet melphalan is a DNA-damaging alkylating agent; therefore, we assessed its mutational effect on surviving myeloma cells by analyzing paired MM samples collected at diagnosis and relapse in the IFM 2009 study. We performed deep whole-genome sequencing on samples from 68 patients, 43 of whom were treated with RVD (lenalidomide, bortezomib, and dexamethasone) and 25 with RVD + HDM. Although the number of mutations was similar at diagnosis in both groups (7137 vs 7230; P = .67), the HDM group had significantly more mutations at relapse (9242 vs 13 383, P = .005). No change in the frequency of copy number alterations or structural variants was observed. The newly acquired mutations were typically associated with DNA damage and double-stranded breaks and were predominantly on the transcribed strand. A machine learning model, using this unique pattern, predicted patients who would receive HDM with high sensitivity, specificity, and positive prediction value. Clonal evolution analysis showed that all patients treated with HDM had clonal selection, whereas a static progression was observed with RVD. A significantly higher percentage of mutations were subclonal in the HDM cohort. Intriguingly, patients treated with HDM who achieved complete remission (CR) had significantly more mutations at relapse yet had similar survival rates as those treated with RVD who achieved CR. This similarity could have been due to HDM relapse samples having significantly more neoantigens. Overall, our study identifies increased genomic changes associated with HDM and provides rationale to further understand clonal complexity.


  • Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study

    by Jean-Baptiste Alberge, Françoise Kraeber-Bodéré, Bastien Jamet, Cyrille Touzeau, Hélène Caillon, Soraya Wuilleme, Marie-Christine Béné, Tobias Kampfenkel, Pieter Sonneveld, Mark van Duin, et al.

    The International Myeloma Working Group has recently fully incorporated 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies have demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these FDG-PET biomarkers could be fully endorsed as risk classifiers by the haematologist community, further characterization of underlying molecular aspects is necessary. Methods: Reported prognostic biomarkers (FDG avidity, SUVmax, number of focal lesions, presence of para-medullary disease (PMD) or extra-medullary disease (EMD)) were extracted from FDG-PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA cohort (ClinicalTrials.gov, NCT02541383). Transcriptomic analyses using RNA sequencing were realized on sorted bone marrow plasma cells from the same patients. Association with high-risk gene expression signature (IFM15), molecular classification, progression-free-survival (PFS), stringent clinical response (sCR) and minimal residual disease (MRD) negativity were explored. Results: FDG-PET was positive in 79.4% of patients, with 14% and 11% of them presenting PMD and EMD respectively. Negative FDG-PET scans were associated with lower expression of hexokinase-2 (HK2) (Fold Change = 2.1, padj=0.04) and enriched for the LB (low-bone disease) subgroup of patients. Positive FDG-PET profiles displayed two distinct signatures with either high expression of proliferation genes, or high expression of GLUT5 and lymphocyte antigens. PMD and IFM15 were independently associated with a lower PFS, and the presence of both biomarkers defined a group of double-positive patients at very high-risk of progression. PMD and IFM15 were neither related to MRD assessment nor to sCR. Conclusion: Our study confirmed and extended the association between imaging biomarkers and transcriptomic programs in MM. Combined prognostic value of PMD and high-risk signature with IFM15 may help define a very high-risk group of MM.